Alkermes plc
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Blair Jackson
- Full Time Employees
- 2,050
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- Connaught House Dublin DU Ireland D04 C5Y6
- IPO Date
- Jul 16, 1991
- CIK
- 0001520262
- Website
- alkermes.com
- Similar Companies
- Business
- Alkermes plc (Nasdaq: ALKS) develops, manufactures and commercializes treatments for central nervous system (CNS) disorders, addiction and oncology. The company offers proprietary products including Vivitrol (extended-release naltrexone injection) for alcohol and opioid use disorders; Aristada and Aristada Initio (aripiprazole lauroxil) for schizophrenia; Lybalvi (olanzapine and samidorphan) for schizophrenia and bipolar I disorder; and Alkermes' oncology portfolio featuring Nemvaleukin alfa, a novel interleukin-2 variant cytokine in clinical development for advanced solid tumors. Alkermes provides contract development and manufacturing services through its Alkermes Pharma subsidiary, specializing in drug formulation, aseptic fill-finish and particle engineering for complex injectable and inhaled therapeutics. Founded in 1987 and headquartered in Waltham, Massachusetts, the company operates primarily in the United States and Ireland, with commercial activities focused on specialty pharmaceuticals for healthcare providers, payers and patients in neurology, addiction and cancer treatment markets. In 2024, Alkermes advanced its oncology pipeline by initiating a Phase 3 clinical trial for nemvaleukin alfa in melanoma following positive Phase 2 data; completed a strategic licensing agreement with Janssen Biotech for a novel CD38-targeting antibody-drug conjugate; and reported a $200 million milestone payment from a prior collaboration while optimizing its neuroscience portfolio through cost-saving measures amid patent expirations.
Company News
Alkermes to Report Third Quarter Financial Results on November 3, 2026
Alkermes to Report Third Quarter Financial Results on November 3, 2026
Earnings Preview: Alkermes (ALKS) Q3 Earnings Expected to Decline
Alkermes plc $ALKS Shares Sold by State of Alaska Department of Revenue
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research
4 CNS Drug Stocks Worth Watching This World Mental Health Day
Stock Picks From Seeking Alpha's September 2026 New Analysts
Critical Survey: Alkermes (NASDAQ:ALKS) and uniQure (NASDAQ:QURE)
LQDA versus ALKS: Which Biotech Stock Is the Better Buy Now?
Alkermes: Idiopathic Hypersomnia Could Expand Lumryz Into A Larger Growth And Margin Driver
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290
How Alkermes Used Its Narcolepsy Playbook In ADHD — And Seemingly Won
Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors
California State Teachers Retirement System Increases Holdings in Alkermes plc $ALKS
Alkermes: A Slow-Burning Buy Prospect On Orexin-Agonist Promise
Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program
Financial Review: C4 Therapeutics (NASDAQ:CCCC) and Alkermes (NASDAQ:ALKS)
Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000
Why Is Alkermes (ALKS) Up 1.7% Since Last Earnings Report?